Literature DB >> 12436176

Omeprazole, furazolidone, and tetracycline: an eradication treatment for resistant H. pylori in Brazilian patients with peptic ulcer disease.

Fernando Marcuz Silva1, Jaime Natan Eisig, Ethel Zimberg Chehter, Júlio Jovino da Silva, Antonio Atílio Laudanna.   

Abstract

OBJECTIVES: To determine the efficacy of a simple, short-term and low-cost eradication treatment for Helicobacter pylori (H. pylori) using omeprazole, tetracycline, and furazolidone in a Brazilian peptic ulcer population, divided into 2 subgroups: untreated and previously treated for the infection. PATIENTS AND METHODS: Patients with peptic ulcer disease diagnosed by endoscopic examination and infected by H. pylori diagnosed by the rapid urease test (RUT) and histological examination, untreated and previously unsuccessfully treated by macrolides and nitroimidazole, were medicated with omeprazole 20 mg daily dose and tetracycline 500 mg and furazolidone 200 mg given 3 times a day for 7 days. Another endoscopy or a breath test was performed 12 weeks after the end of treatment. Patients were considered cured of the infection if a RUT and histologic examination proved negative or a breath test was negative for the bacterium.
RESULTS: Sixty-four patients were included in the study. The women were the predominant sex (58%); the mean age was 46 years. Thirty-three percent of the patients were tobacco users, and duodenal ulcer was identified in 80% of patients. For the 59 patients that underwent follow-up examinations, eradication was verified in 44 (75%). The eradication rate for the intention-to-treat group was 69%. The incidence of severe adverse effects was 15%.
CONCLUSION: The treatment provides good efficacy for H. pylori eradication in patients who were previously treated without success, but it causes severe adverse effects that prevented adequate use of the medications in 15% of the patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12436176     DOI: 10.1590/s0041-87812002000500003

Source DB:  PubMed          Journal:  Rev Hosp Clin Fac Med Sao Paulo        ISSN: 0041-8781


  4 in total

Review 1.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

2.  Comparison of quadruple and triple Furazolidone containing regimens on eradication of helicobacter pylori.

Authors:  Marjan Mokhtare; Vahid Hosseini; Hafez Tirgar Fakheri; Iradj Maleki; Tarang Taghvaei; Seyed Mohammad Valizadeh; Hossein Sardarian; Shahram Agah; Alireza Khalilian
Journal:  Med J Islam Repub Iran       Date:  2015-04-06

3.  Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.

Authors:  Tomás Navarro-Rodriguez; Fernando Marcuz Silva; Ricardo Correa Barbuti; Rejane Mattar; Joaquim Prado Moraes-Filho; Maricê Nogueira de Oliveira; Cristina S Bogsan; Décio Chinzon; Jaime Natan Eisig
Journal:  BMC Gastroenterol       Date:  2013-03-26       Impact factor: 3.067

4.  Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.

Authors:  Jaime N Eisig; Fernando M Silva; Ricardo C Barbuti; Tomás Navarro Rodriguez; Peter Malfertheiner; Joaquim P P Moraes Filho; Schlioma Zaterka
Journal:  BMC Gastroenterol       Date:  2009-05-26       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.